Endothelin-1 Inhibition by Ambrisentan as a Potential Treatment Adjunct After Debulking Surgery in Epithelial Ovarian Cancer

Author: Kast, R. E.

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 17, Number 8, 2009 , pp. 383-386(4)

Publisher: Cognizant Communication Corporation

Buy & download fulltext article:

Price: $79.00 plus tax (Refund Policy)

Abstract:

The 21 amino acid signaling peptide endothelin-1 is commonly elevated in epithelial ovarian cancer, and it mediates or facilitates much of this cancer's aggressive behavior. Ambrisentan (Letairis; Gilead Sciences Inc.) is an antagonist of endothelin-1 at its cognate receptor that has just been approved to treat pulmonary hypertension. Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery.

Keywords: Ambrisentan; Endothelin; Epithelial ovarian cancer; Micrometastases; Metaplasia

Document Type: Commentary

DOI: http://dx.doi.org/10.3727/096504009788428433

Publication date: 2009-01-01

More about this publication?

Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.